Preanalgesic Effect of Gabapentin in Total Knee Repair

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2006 by Texas Health Resources.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Texas Health Resources
ClinicalTrials.gov Identifier:
NCT00279487
First received: January 16, 2006
Last updated: February 27, 2007
Last verified: January 2006
  Purpose

The purpose of this study is to determine whether gabapentin, as a one time administration prior to a total knee replacement procedure, has opioid sparing effects and a reduction in pain scores.


Condition Intervention
Pain
Drug: Gabapentin

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Texas Health Resources:

Estimated Enrollment: 60
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients undergoing total knee replacement who received pain management by the following modality:

    • Intravenous patient-controlled analgesia (IV-PCA) opioid
    • Local femoral nerve block with 1.5% mepivacaine 20 ml and 0.5% ropivacaine 20 ml

Exclusion Criteria:

  • Age < 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00279487

Contacts
Contact: Rob Hutchison, PharmD 214-345-2493 robhutchison@texashealth.org

Locations
United States, Texas
Presbyterian Hospital of Dallas Recruiting
Dallas, Texas, United States, 75231
Contact: Rob Hutchison    214-345-2493    robhutchison@texashealth.org   
Contact: Denise Stamos    214-345-2966    denisestamos@texashealth.org   
Principal Investigator: William Tucker         
Sub-Investigator: Jeffrey Pirinelli         
Sub-Investigator: Joy Aguwa         
Sponsors and Collaborators
Texas Health Resources
Investigators
Principal Investigator: Rob Hutchison Texas Health Resources
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00279487     History of Changes
Other Study ID Numbers: P768
Study First Received: January 16, 2006
Last Updated: February 27, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Texas Health Resources:
Patients undergoing total knee replacement who received pain management by the following modality:
IV PCA opioid
Local femoral nerve block with 1.5% Mepivacaine & 0.5% Ropivacaine

Additional relevant MeSH terms:
Gabapentin
Analgesics
Anti-Anxiety Agents
Anti-Dyskinesia Agents
Anticonvulsants
Antimanic Agents
Antiparkinson Agents
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on October 23, 2014